These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 24387108

  • 1. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL.
    Mol Cancer; 2014 Jan 03; 13():2. PubMed ID: 24387108
    [Abstract] [Full Text] [Related]

  • 2. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.
    PLoS One; 2013 Jan 03; 8(6):e66589. PubMed ID: 23818948
    [Abstract] [Full Text] [Related]

  • 3. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 4. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 Nov 20; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 5. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 6. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.
    Int J Mol Med; 2013 Jun 01; 31(6):1449-56. PubMed ID: 23588698
    [Abstract] [Full Text] [Related]

  • 7. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 9. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 10; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 10. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 10; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 11. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK.
    PLoS One; 2014 Nov 10; 9(4):e95588. PubMed ID: 24743574
    [Abstract] [Full Text] [Related]

  • 12. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.
    PLoS One; 2013 Nov 10; 8(3):e59879. PubMed ID: 23533654
    [Abstract] [Full Text] [Related]

  • 13. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines.
    Glienke W, Maute L, Wicht J, Bergmann L.
    Tumour Biol; 2012 Jun 10; 33(3):757-65. PubMed ID: 22170433
    [Abstract] [Full Text] [Related]

  • 14. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
    Kim H, Lee SJ, Lee IK, Min SC, Sung HH, Jeong BC, Lee J, Park SH.
    Int J Mol Sci; 2020 Apr 18; 21(8):. PubMed ID: 32325639
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K, Hamacher A, Engelke LH, Kassack MU.
    BMC Cancer; 2017 Nov 03; 17(1):711. PubMed ID: 29100507
    [Abstract] [Full Text] [Related]

  • 16. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, Song L, Xu R, Ma Y, Cai S, Tang X.
    Biomed Res Int; 2021 Nov 03; 2021():5556306. PubMed ID: 33987439
    [Abstract] [Full Text] [Related]

  • 17. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN.
    Oncotarget; 2014 May 15; 5(9):2372-89. PubMed ID: 24796583
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 May 15; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 20. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 15; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.